243 related articles for article (PubMed ID: 22607183)
1. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade.
Karoopongse E; Deeg HJ
Expert Rev Clin Immunol; 2012 May; 8(4):373-81. PubMed ID: 22607183
[TBL] [Abstract][Full Text] [Related]
2. Current status of allogeneic hematopoietic cell transplantation for MDS.
Xu F; Deeg HJ
Curr Pharm Des; 2012; 18(22):3215-21. PubMed ID: 22571701
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.
Deeg HJ; Bartenstein M
Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):31-41. PubMed ID: 22143157
[TBL] [Abstract][Full Text] [Related]
5. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
[TBL] [Abstract][Full Text] [Related]
6. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?
Gyurkocza B; Deeg HJ
Blood Rev; 2012 Nov; 26(6):247-54. PubMed ID: 22981712
[TBL] [Abstract][Full Text] [Related]
10. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
11. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
12. Transplantation for myelodysplastic syndromes 2013.
Vaughn JE; Scott BL; Deeg HJ
Curr Opin Hematol; 2013 Nov; 20(6):494-500. PubMed ID: 24104409
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic cell transplantation for myelodysplastic syndrome.
Deeg HJ
Am Soc Clin Oncol Educ Book; 2015; ():e375-80. PubMed ID: 25993199
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?
Marcondes M; Deeg HJ
Best Pract Res Clin Haematol; 2008 Mar; 21(1):67-77. PubMed ID: 18342814
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
[TBL] [Abstract][Full Text] [Related]
16. Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome.
Festuccia M; Deeg HJ; Gooley TA; Baker K; Wood BL; Fang M; Sandmaier BM; Scott BL
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1227-1233. PubMed ID: 27064057
[TBL] [Abstract][Full Text] [Related]
17. Transplant strategies for patients with myelodysplastic syndromes.
Deeg HJ
Curr Opin Hematol; 2006 Mar; 13(2):61-6. PubMed ID: 16456370
[TBL] [Abstract][Full Text] [Related]
18. Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study.
Choi EJ; Lee JH; Lee JH; Kim DY; Park HS; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
Ann Hematol; 2016 Jun; 95(7):1151-61. PubMed ID: 27106699
[TBL] [Abstract][Full Text] [Related]
19. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
20. Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease.
Burroughs L; Storb R
Curr Opin Hematol; 2005 Jan; 12(1):45-54. PubMed ID: 15604891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]